title: Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
abstract: In our previous study we found that MCF-7 cells possess aromatase activity and stimulate estrogen receptor-mediated growth. The pathways through which androgens are converted to estrogens by aromatase and estrogens interact with estrogen receptors contribute significantly to growth stimulation. The administration of aromatase inhibitor results in suppression of growth stimulation by androgens. This system enabled us to assess directly the biological activities of aromatase inhibitors. Aromatase activity was inhibited in a dose-dependent manner by the addition of aminoglutethimide and CGS 16949A, competitive inhibitors, and of 14 alpha-hydroxy-4-androstene-3,6,17-trione and 4-hydroxy-androstenedione, mechanism-based inhibitors. After preincubation with mechanism-based inhibitors, aromatase activity was significantly suppressed, whereas after preincubation with competitive inhibitors, it was adversely increased. These effects were concentration- and time-dependent. Preincubation with competitive inhibitors resulted in augmentation of subsequent androgen stimulation of thymidine incorporation, while preincubation with mechanism-based inhibitors resulted in diminished stimulation by subsequent androgen administration. These results suggest that in MCF-7 cells competitive inhibitors adversely induce aromatase and accelerate the subsequent androgen stimulation of DNA synthesis. Suicide inhibitors are more effective than competitive inhibitors. This system will be useful for aromatase inhibitor screening.
authors: Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Japan.
authors: J
authors: J
authors: Kitawaki
authors: T
authors: T
authors: Kim
authors: H
authors: H
authors: Kanno
authors: T
authors: T
authors: Noguchi
authors: T
authors: T
authors: Yamamoto
authors: H
authors: H
authors: Okada
mesh_terms: D000616:Aminoglutethimide / Q000494:pharmacology*; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000737:Androstenols / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001141:Aromatase / Q000378:metabolism*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms; D002455:Cell Division / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D017316:Fadrozole / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007700:Kinetics; D014407:Tumor Cells, Cultured
chemical_list: D000737:Androstenols; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D000616:Aminoglutethimide; C067637:14-hydroxyandrost-4-ene-3,6,17-trione; D000735:Androstenedione; D001141:Aromatase; D017316:Fadrozole; C014594:formestane